| scholarly article | Q13442814 |
| P356 | DOI | 10.1046/J.1365-2362.2000.00735.X |
| P698 | PubMed publication ID | 11114960 |
| P50 | author | Marilena Formato | Q43122578 |
| P2093 | author name string | G Tonolo | |
| A Carboni | |||
| M Ciccarese | |||
| G M Cherchi | |||
| M Maioli | |||
| M G Melis | |||
| M F Angius | |||
| P Brizzi | |||
| P2860 | cites work | Impaired endothelium-dependent vasodilation in patients with insulin-dependent diabetes mellitus. | Q54225577 |
| Analysis of nitrate, nitrite, and [15N]nitrate in biological fluids | Q29616817 | ||
| Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group | Q29619842 | ||
| Beyond lipids - the role of the endothelium in coronary artery disease | Q33780878 | ||
| Upregulation of endothelial nitric oxide synthase by HMG CoA reductase inhibitors | Q34463540 | ||
| The progression of renal disease | Q34661353 | ||
| Restoration of endothelium-dependent relaxation by dietary treatment of atherosclerosis | Q35584108 | ||
| Vitamin C improves endothelium-dependent vasodilation in patients with non-insulin-dependent diabetes mellitus | Q37350875 | ||
| Risk factors for death in treated hypertensive patients. Report from the D.H.S.S. Hypertension Care Computing Project | Q39555228 | ||
| Lovastatin ameliorates the development of glomerulosclerosis and uremia in experimental nephrotic syndrome | Q41896190 | ||
| Simvastatin inhibits PDGF-induced DNA synthesis in human glomerular mesangial cells | Q42286505 | ||
| Microalbuminuria predicts clinical proteinuria and early mortality in maturity-onset diabetes | Q43511438 | ||
| Urinary infection and albumin excretion in insulin-dependent diabetes mellitus: implications for the measurement of microalbuminuria | Q44076801 | ||
| Low-sulfated chondroitin sulfate in human blood and urine | Q44448427 | ||
| Partial remission of nephrotic syndrome in patient on long-term simvastatin | Q44947481 | ||
| Effect of partial ileal bypass surgery on mortality and morbidity from coronary heart disease in patients with hypercholesterolemia. Report of the Program on the Surgical Control of the Hyperlipidemias (POSCH) | Q44966192 | ||
| Main risk factors for nephropathy in type 2 diabetes mellitus are plasma cholesterol levels, mean blood pressure, and hyperglycemia. | Q50888604 | ||
| Transcapillary escape rate of albumin in type II diabetic patients. The relationship with microalbuminuria and hypertension. | Q50953880 | ||
| Urinary albumin excretion, cardiovascular disease, and endothelial dysfunction in non-insulin-dependent diabetes mellitus | Q52859992 | ||
| Nitric oxide availability in diabetes mellitus. | Q54116711 | ||
| P433 | issue | 11 | |
| P921 | main subject | simvastatin | Q670131 |
| P304 | page(s) | 980-987 | |
| P577 | publication date | 2000-11-01 | |
| P1433 | published in | European Journal of Clinical Investigation | Q15745208 |
| P1476 | title | Additive effects of Simvastatin beyond its effects on LDL cholesterol in hypertensive type 2 diabetic patients | |
| P478 | volume | 30 |
| Q36519198 | A model of long-term metabolic progression of type 2 diabetes mellitus for evaluating treatment strategies |
| Q44441967 | About the pleiotropic effects of statins in human |
| Q43199880 | Acute effects of atorvastatin on glomerular filtration rate, tubular function, blood pressure, and vasoactive hormones in patients with type 2 diabetes |
| Q36829002 | Analysis of antihypertensive effects of statins. |
| Q35068761 | Apolipoprotein E polymorphism and atherosclerosis |
| Q37086076 | Augmentation of the renin-angiotensin system by hypercholesterolemia promotes vascular diseases. |
| Q44827945 | Autoantibodies against oxidized low-density lipoprotein (ox-LDL) and LDL oxidation status |
| Q35681170 | Blood pressure control and factors predicting control in a treatment-compliant male veteran population |
| Q44705841 | Cognitive impairment associated with atorvastatin and simvastatin |
| Q36847085 | Do statins lower blood pressure? |
| Q38188802 | Dyslipidemia and progression of kidney disease: role of lipid-lowering drugs |
| Q36364965 | Dyslipidemia of chronic renal failure: the nature, mechanisms, and potential consequences |
| Q46482440 | Effect of atorvastatin on renal NO availability and tubular function in patients with stage II-III chronic kidney disease and type 2 diabetes. |
| Q63681912 | Effect of pravastatin on blood pressure in people with cardiovascular disease |
| Q45234469 | Effect of pravastatin on development of left ventricular hypertrophy in spontaneously hypertensive rats |
| Q38781141 | Effect of statins on blood pressure: Analysis on adverse events released by FDA. |
| Q37661029 | Effects of simvastatin on blood pressure in hypercholesterolemic patients: An open-label study in patients with hypertension or normotension |
| Q36302838 | Emerging drugs for diabetic nephropathy |
| Q36936335 | Endothelial function, arterial stiffness and lipid lowering drugs |
| Q84978295 | Evidence-based practice guideline for the treatment of CKD |
| Q80316010 | HMG-CoA reductase inhibitors and the kidney |
| Q46966042 | How to choose a statin after kidney transplantation: case analyses |
| Q34990490 | Hypertension and lipids: lipid factors in the hypertension syndrome |
| Q44520782 | Hypolipidemic and anti-atherogenic effects of long-term Cholestin (Monascus purpureus-fermented rice, red yeast rice) in cholesterol fed rabbits |
| Q36467559 | Interaction of oxidized low-density lipoprotein and the renin-angiotensin system in coronary artery disease |
| Q37245464 | Kidney function and estimated vascular risk in patients with primary dyslipidemia |
| Q40570182 | Leukocytosis, hypoalbuminemia, and the risk for chronic kidney disease in US adults |
| Q46864906 | Lovastatin inhibits oxidized low-density lipoprotein-induced plasminogen activator inhibitor and transforming growth factor-beta1 expression via a decrease in Ras/extracellular signal-regulated kinase activity in mesangial cells |
| Q54568444 | Managing chronic kidney disease in type 2 diabetes in family practice. |
| Q37780943 | National Kidney Foundation consensus conference on cardiovascular and kidney diseases and diabetes risk: an integrated therapeutic approach to reduce events |
| Q57750598 | No detrimental effect on renal function during long-term use of fluvastatin in renal transplant recipients in the Assessment of Lescol in Renal Transplantation (ALERT) study |
| Q37594792 | Pharmacotherapy of hyperglycemia |
| Q44123157 | Policosanol safely down-regulates HMG-CoA reductase - potential as a component of the Esselstyn regimen |
| Q55053682 | Protection Against Nephropathy in Diabetes with Atorvastatin (PANDA): a randomized double-blind placebo-controlled trial of high- vs. low-dose atorvastatin(1). |
| Q54600827 | Simvastatin maintains steady patterns of GFR and improves AER and expression of slit diaphragm proteins in type II diabetes. |
| Q42169686 | Simvastatin reverses cardiac hypertrophy caused by disruption of the bradykinin 2 receptor |
| Q46548071 | Statin therapy helps to control blood pressure levels in hypertensive dyslipidemic patients |
| Q36558703 | Statin therapy in patients with chronic kidney disease: to use or not to use. |
| Q34317621 | Statins and blood pressure regulation. |
| Q36836591 | Statins and blood pressure: is there an effect or not? |
| Q36232369 | Statins and proteinuria |
| Q34940824 | Statins and renal function |
| Q34662787 | Statins: a perspective for left ventricular hypertrophy treatment |
| Q36411099 | Statins: another class of antihypertensive agents? |
| Q37133400 | The effect of biliary sphincterotomy on serum cholesterol level in postcholecystectomy patients: a pilot study |
| Q44753301 | The effect of short-term treatment with simvastatin on renal function in patients with peripheral arterial disease |
| Q43017133 | The pleiotropic actions of rosuvastatin confer renal benefits in the diabetic Apo-E knockout mouse. |
| Q73315625 | Treating dyslipidemia to slow the progression of chronic renal failure |
| Q41463382 | Urinary Neutrophil Gelatinase-Associated Lipocalin Is Complementary to Albuminuria in Diagnosis of Early-Stage Diabetic Kidney Disease in Type 2 Diabetes |
Search more.